痰热清注射液对退行性心力衰竭合并肺部感染患者的辅助治疗效果  

Effect of Tanreqing Injection in adjuvant treatment of patients with degenerative heart failure complicated with pulmonary infection

作　　者：赵娜 姚小青[1] 胡丽娜[1] ZHAO Na;YAO Xiao-qing;HU Li-na(Department of Respiratory and Critical Care Medicine,Baoji Hospital of Traditional Chinese Medicine,Baoji 721000,Shaanxi,CHINA)

机构地区：[1]宝鸡市中医医院呼吸与危重症医学科,陕西宝鸡721000

出　　处：《海南医学》2022年第12期1508-1511,共4页Hainan Medical Journal

基　　金：陕西省宝鸡市2017年度科研立项课题(编号:2017-16)。

摘　　要：目的观察痰热清注射液对退行性心力衰竭合并肺部感染患者的辅助治疗效果。方法选取宝鸡市中医医院呼吸与危重症医学2019年1月至2020年12月收治的86例退行性心力衰竭合并肺部感染患者为研究对象,采用简单随机分组法将患者分为对照组和观察组各43例。对照组患者给予常规治疗,观察组患者在对照组治疗的基础上给予痰热清注射液治疗,均治疗7 d。比较两组患者治疗前后的左心室收缩末期内径(LVSD)、左心室舒张末期内径(LVDD)、左心室射血分数(LVEF)、第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)、FEV_(1)/FVC、血清C反应蛋白(hs-CRP)和白细胞介素6(IL-6)水平;比较两组患者的治疗效果和不良反应发生情况。结果治疗后,观察组和对照组患者的LVSD[(40.59±6.14)mm vs(45.81±6.25)mm]、LVDD[(50.63±6.97)mm vs(57.28±7.11)mm]水平比较,观察组明显低于对照组,LVEF[(53.04±7.23)%vs(46.05±6.87)%]比较,观察组明显高于对照组,差异均具有统计学意义(P<0.05);治疗后,观察组和对照组患者的FEV_(1)[(1.71±0.43)L vs(1.45±0.39)L]、FVC[(2.73±0.49)L vs(2.29±0.42)L]及FEV_(1)/FVC[(78.35±3.26)%vs(65.16±3.35)%]水平比较,观察组明显高于对照组,差异均具有统计学意义(P<0.05);治疗后,观察组和对照组患者的hs-CRP[(14.43±3.55)mg/L vs(18.54±3.86)mg/L]及IL-6[(13.96±3.28)ng/L vs(19.13±3.35)ng/L]水平比较,观察组明显低于对照组,差异均有统计学意义(P<0.05);观察组患者的治疗总有效率为93.02%,明显高于对照组的76.74%,差异有统计学意义(P<0.05);两组患者治疗期间均观察到心律失常及肌肉酸痛等不良反应,但组间不良反应总发生率比较差异无统计学意义(P>0.05)。结论痰热清注射液辅助治疗退行性心力衰竭合并肺部感染有助于减轻患者肺部炎性反应,改善心肺功能,临床应用效果显著,且临床用药具有一定的安全性。Objective To observe the adjuvant therapeutic effect of Tanreqing Injection on patients with degenerative heart failure complicated with pulmonary infection.Methods Eighty-six patients with degenerative heart failure complicated with pulmonary infection treated in Department of Respiratory and Critical Care Medicine,Baoji Hospital of Traditional Chinese Medicine from January 2019 to December 2020 were selected as the research objects.The patients were divided into a control group and a study group by simple random grouping method,each with 43 patients.The patients in the control group were treated with routine treatment,and the patients in the study group were treated with Tanreqing Injection on the basis of the treatment in the control group,for 7 days.After treatment,the levels of left ventricular end systolic diameter(LVSD),left ventricular end diastolic diameter(LVDD),left ventricular ejection fraction(LVEF),forced expiratory volume in the first second(FEV_(1)),forced vital capacity(FVC),FEV_(1)/FVC,serum C-reactive protein(hs-CRP),and interleukin-6(IL-6)were compared between the two groups.The therapeutic effects and adverse reactions of the two groups were compared.Results After treatment,the levels of LVSD and LVDD in the study group were(40.59±6.14)mm and(50.63±6.97)mm,significantly lower than(45.81±6.25)mm and(57.28±7.11)mm in the control group,and the level of LVEF was(53.04±7.23)%in the study group,significantly higher than(46.05±6.87)%in the control group(P<0.05).After treatment,the levels of FEV_(1),FVC,and FEV_(1)/FVC in the study group were significantly higher than those in the control group(P<0.05):FEV_(1),(1.71±0.43)L vs(1.45±0.39)L;FVC,(2.73±0.49)L vs(2.29±0.42)L;FEV_(1)/FVC,(78.35±3.26)%vs(65.16±3.35)%.After treatment,the levels of hs-CRP and IL-6 in the study group were significantly lower than those in the control group(P<0.05):hs-CRP,(14.43±3.55)mg/L vs(18.54±3.86)mg/L;IL-6,(13.96±3.28)ng/L vs(19.13±3.35)ng/L.The total effective rate of the study group was 93.02%,which was s

关 键 词：痰热清注射液 退行性心力衰竭 肺部感染 心肺功能 炎性反应 疗效 不良反应 

分 类 号：R541.6[医药卫生—心血管疾病]